Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 8/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 8/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 8/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 7/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 6/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 6/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.78 |
| ▸ | GABRP | O00591 | 1/20 | 0.68 |
| ▸ | GABRD | O14764 | 1/20 | 0.68 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.68 |
| ▸ | ALB | P02768 | 1/20 | 0.68 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.68 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.68 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.68 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.68 |
| ▸ | GABRE | P78334 | 1/20 | 0.68 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.68 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29588960 | 0.88 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3GABRG2 | |
| SCHEMBL2871536 | 0.88 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3GABRG2 | |
| SCHEMBL5042562 | 0.88 | GABRA1 (0.78) | GABRA1GABRA5GABRA2GABRA3GABRG2 | |
| SCHEMBL11256869 | 0.85 | GABRA1 (0.80) | GABRA1GABRA5GABRA2GABRA3GABRG2 | |
| SCHEMBL7724678 | 0.85 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3GABRG2 | |
| Diazepam SCHEMBL21641843 | 0.83 | GABRA1 (0.88) | GABRA1GABRA5GABRA2GABRA3GABRG2 | |
| SCHEMBL5034709 | 0.83 | GABRA1 (0.71) | GABRA1GABRA5GABRA2GABRA3GABRG2 | |
| SCHEMBL5038321 | 0.83 | GABRA1 (0.71) | GABRA1GABRA5GABRA2GABRA3GABRG2 | |
| Diazepam SCHEMBL3043280 | 0.82 | GABRA1 (0.97) | GABRA1GABRA5GABRA2GABRA3GABRG2 | |
| SCHEMBL24194446 | 0.82 | GABRA1 (0.74) | GABRA1GABRA5GABRA2GABRA3GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390311-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-28 | — | — | US | claimed |
| EP-4405049-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS | The Regents of the University of California (US) | 2024-07-31 | — | — | EP | claimed |
| US-20230381125-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-30 | — | — | US | claimed |
| EP-4217002-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS | The Regents of the University of California (US) | 2023-08-02 | — | — | EP | claimed |
| WO-2023101899-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING SJOGREN'S SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-08 | — | — | WO | claimed |
| WO-2023048781-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-30 | — | — | WO | claimed |
| WO-2022067044-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-31 | — | — | WO | claimed |
| US-20220079952-A1 | Uses of Radiation and Benzodiazepine Derivatives in Cancer Therapies | UNIV EMORY (US) | 2022-03-17 | — | — | US | claimed |
| US-20250313537-A1 | BENZODIAZEPINE ANALOGS AND METHODS OF USE IN TREATING CANCER | UNIVERSITY OF CINCINNATI (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | SWITCH BIO, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250152742-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2025-05-15 | — | — | US | disclosed |
| US-20240390311-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-28 | — | — | US | disclosed |
| US-20240317834-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2024-09-26 | — | — | US | disclosed |
| EP-4405049-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS | The Regents of the University of California (US) | 2024-07-31 | — | — | EP | disclosed |
| US-20220348635-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2022-11-03 | — | — | US | disclosed |
| EP-4017874-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | Coda Biotherapeutics, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-2022067044-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-31 | — | — | WO | disclosed |
| US-20220079952-A1 | Uses of Radiation and Benzodiazepine Derivatives in Cancer Therapies | UNIV EMORY (US) | 2022-03-17 | — | — | US | disclosed |
| US-4327026-A | Benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 1982-04-27 | — | — | US | disclosed |
| EP-0045452-A2 | Benzodiazepine derivatives, intermediates and their preparation, and pharmaceutical compositions containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220079952-A1 | Uses of Radiation and Benzodiazepine Derivatives in Cancer Therapies | GABBR1, GABBR2, GABRA3 | GABRA1 5/4885GABRA5 8/4885GABRA2 7/4885 |
| US-20250152742-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | GABRA1 138/4885GABRA5 152/4885GABRA2 82/4885 |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | CACNB2, CHRNA2, HCN3 | GABRA1 175/4885GABRA5 184/4885GABRA2 139/4885 |
| US-20240317834-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | GABRA1 138/4885GABRA5 152/4885GABRA2 82/4885 |
| US-20250313537-A1 | BENZODIAZEPINE ANALOGS AND METHODS OF USE IN TREATING CANCER | GABRA3, GABRB3, GABRA4 | GABRA1 6/4885GABRA5 5/4885GABRA2 8/4885 |
| US-20220348635-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | GABRA1 138/4885GABRA5 152/4885GABRA2 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.